When the first round of i2b2 was proposed. It was not anticipated that the very significant adoption and dissemination (see Progress Report) would have occurred within the first five years. Rather it was seen as a development likely to occur in an eventual second round of i2b2 funding. With half of the CTSA awardees adopting all or part of i2b2, as well as dozens of other academic medical centers, national and internationally, and the members ofthe private sector (pharmaceutical Industry and technology providers) there has emerged a community of public-spirited developers commercial developers who have created additional functionality, alternate functionality and improvements over the existing I2b2 code base. This includes ontology services, EDO applications. Image transport and storage, distributed queries across multiple i2b2 instances, and data visualization, to name but a few. We are responding to this opportunity by planning a full-fledged communityengaged open source process. We do so with a governance structure that is inclusive and that calls for rotating membership. We also do it with an eye to having a continuing and lasting i2b2 effort once NCBC funding ends. Importantly we have described in the detail of Core 3 a transparent process for deciding which community additions are included as core or ancillary within the i2b2 software distribution and how the integration/test/debug/documentation cycle for each contribution is queued. In addition to this community engagement a central function of Core 3 will be to maintain the core i2b2 software platform such that it Is able to support the national and regional installations of the softvvare and assure their continued operation. This includes the internal operations of i2b2 and its DBPs, as well as the external sites who have adopted i2b2. A professional open-source software approach will be used to maintain the software in so far that there will be two distinct approaches to the i2b2 software. There will be a wholeproduct offering that will be supported with industrial partnerships and offer those adopting the I2b2 platform a stable, well supported version ofthe I2b2 platform, and there will be a offering forthe community which is geared toward making available the latest code and technical specifications. This leads to the second specific aim of core 3 which is the establishment of several standard distributions that will be based upon a virtual machine (VM) architecture. This will ensure a secure and manageable installation

National Institute of Health (NIH)
National Library of Medicine (NLM)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BST-K)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Manrai, Arjun K; Funke, Birgit H; Rehm, Heidi L et al. (2016) Genetic Misdiagnoses and the Potential for Health Disparities. N Engl J Med 375:655-65
Ananthakrishnan, Ashwin N; Cagan, Andrew; Cai, Tianxi et al. (2016) Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 14:973-9
Castro, V M; Kong, S W; Clements, C C et al. (2016) Absence of evidence for increase in risk for autism or attention-deficit hyperactivity disorder following antidepressant exposure during pregnancy: a replication study. Transl Psychiatry 6:e708
Savova, Virginia; Chun, Sung; Sohail, Mashaal et al. (2016) Genes with monoallelic expression contribute disproportionately to genetic diversity in humans. Nat Genet 48:231-7
Nazeen, Sumaiya; Palmer, Nathan P; Berger, Bonnie et al. (2016) Integrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbidities. Genome Biol 17:228
Lerin, Carles; Goldfine, Allison B; Boes, Tanner et al. (2016) Defects in muscle branched-chain amino acid oxidation contribute to impaired lipid metabolism. Mol Metab 5:926-36
Manrai, Arjun K; Wang, Brice L; Patel, Chirag J et al. (2016) REPRODUCIBLE AND SHAREABLE QUANTIFICATIONS OF PATHOGENICITY. Pac Symp Biocomput 21:231-42
Lin, Chen; Dligach, Dmitriy; Miller, Timothy A et al. (2016) Multilayered temporal modeling for the clinical domain. J Am Med Inform Assoc 23:387-95
Ananthakrishnan, Ashwin N; Cagan, Andrew; Cai, Tianxi et al. (2016) Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis 22:880-5
Ananthakrishnan, Ashwin N; Cagan, Andrew; Cai, Tianxi et al. (2016) Identification of Nonresponse to Treatment Using Narrative Data in an Electronic Health Record Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis 22:151-8

Showing the most recent 10 out of 291 publications